Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anemia
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Masking Description: This is an open-label, Sponsor-blind study.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study consists of three periods: Screening Period Conversion and Maintenance Treatment Period Safety Follow-up Period Individual participants will participate in total trial duration of approximately 64 weeks.
This study consists of three periods: Screening Period Conversion and Maintenance Treatment Period Safety Follow-up Period Individual participants will participate in total trial duration of approximately 64 weeks.
Tracking Information
- NCT #
- NCT04313153
- Collaborators
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Investigators
- Not Provided
Get Well Soon